More merging in the biotech areas of healthcare...BD
Pfizer expands in oncology and buys biotech firm Serenex
Just a fortnight after snapping up Encysive Pharmaceuticals, Pfizer has announced plans to acquire Serenex, a privately-held biotechnology company that specialises in oncology.
No financial details of the deal were disclosed but for the money it is paying out, Pfizer is acquiring the rights to SNX-5422, an oral heat shock protein 90 inhibitor which is currently in Phase I trials for the potential treatment of solid tumours and haematological malignancies. The New York-based behemoth is also acquiring Serenex’ proprietary drug discovery technology and “extensive small molecule Hsp90 inhibitor compound library”, which has potential uses in treating cancer, inflammatory and neurodegenerative diseases.
PharmaTimes | Industry News | World News | Pfizer expands in oncology and buys biotech firm Serenex
Hi!
ReplyDeleteThis is Nice Blog!
Drug rehabilitation tends to address a stated twofold nature of drug dependency: physical and psychological dependency. Physical dependency involves a detoxification process to cope with withdrawal symptoms from regular use of a drug. With regular use of many drugs, legal or otherwise, the brain gradually adapts to the presence of the drug so that the desired effect is minimal. Apparently normal functioning of the user may be observed, despite being under the influence of the drug. This is how physical tolerance develops to drugs such as heroin, amphetamines, cocaine, nicotine or alcohol. It also explains why more of the drug is needed to get the same effect with regular use. The abrupt cessation of taking a drug can lead to withdrawal symptoms where the body may take weeks or months (depending on the drug involved) to return to normal.Drug Rehabilitation Center makes rehab from drugs!